Ipca Laboratories Limited (IPCALAB.BO)
- Previous Close
1,327.65 - Open
1,333.75 - Bid --
- Ask --
- Day's Range
1,329.20 - 1,342.55 - 52 Week Range
670.00 - 1,373.95 - Volume
4,551 - Avg. Volume
21,034 - Market Cap (intraday)
339.608B - Beta (5Y Monthly) 0.23
- PE Ratio (TTM)
60.03 - EPS (TTM)
22.30 - Earnings Date May 27, 2024 - May 31, 2024
- Forward Dividend & Yield 2.00 (0.15%)
- Ex-Dividend Date Nov 22, 2023
- 1y Target Est
835.80
Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetology, dermatology, gastroenterology, hematology, neurology, ophthalmology, rheumatology, and urology, as well as psychiatry, probiotics, respiratory, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.
www.ipca.com16,167
Full Time Employees
March 31
Fiscal Year Ends
Sector
Related News
Performance Overview: IPCALAB.BO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IPCALAB.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IPCALAB.BO
Valuation Measures
Market Cap
336.83B
Enterprise Value
346.33B
Trailing P/E
59.67
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.71
Price/Book (mrq)
5.48
Enterprise Value/Revenue
4.85
Enterprise Value/EBITDA
25.63
Financial Highlights
Profitability and Income Statement
Profit Margin
7.85%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
71.87B
Net Income Avi to Common (ttm)
5.64B
Diluted EPS (ttm)
22.30
Balance Sheet and Cash Flow
Total Cash (mrq)
9.34B
Total Debt/Equity (mrq)
26.29%
Levered Free Cash Flow (ttm)
--
Research Analysis: IPCALAB.BO
Company Insights: IPCALAB.BO
IPCALAB.BO does not have Company Insights